Anna Arviz from 21 August 2018 will enter a new position Vice group President and General Director of Avon in Russia and Eastern Europe, the company said.
Anna Arvic 30 June 2018 resigned as senior Vice President, head of cluster Teva Russia and Eurasia and CEO of Teva for Russia, which has held since the beginning of 2014
Under her leadership, in October 2014 in Yaroslavl opened production site for Teva production of solid dosage forms with a capacity of up to two billion tablets a year. In 2016 she has implemented in its area of geographic responsibility of a strategic project for the merger of Teva and Actavis, which resulted in the joint business entered TOP-5 of leaders of the Russian pharmaceutical market and has become the fourth largest global Teva.
Before switching to Teva Anna Arvic have held senior positions in international pharmaceutical companies like Zentiva (Sanofi group of companies) and Ratiopharm. Earlier stage of its career is associated with the guiding posts in sales and marketing of the company SmithKline Beecham (now GlaxoSmithKline).
In his new post Anna Jarvic will be responsible for business development of Avon in Russia, Ukraine, Georgia, Kazakhstan and Kyrgyzstan.
“I am pleased to join the legendary Avon and become part of an organization which prides itself in giving its representatives the opportunity to develop the business and to adapt to new digital realities in Eastern Europe”, – commented on his appointment Anna Arvic.